文献速递心脑血管急症重症综合管理与镇静镇痛

SGLT2抑制剂作为急性心肌梗死合并心源性休克幸存者的出院药物

Sodium-Glucose Cotransporter 2 Inhibitors as Discharge Medications in Survivors of Acute Myocardial Infarction Complicated by Cardiogenic Shock.
PubMed 文献 · Shock · 2026-06-30
一句话结论回顾性多中心队列显示,AMI-CS幸存者出院时处方SGLT2抑制剂与1年心脏死亡无显著降低相关,但数值趋势有利且安全性可接受。

该回顾性多中心队列纳入826例AMI-CS存活出院患者,197例(23.8%)出院时接受SGLT2抑制剂。采用IPTW校正34项基线协变量后,SGLT2抑制剂与1年心脏死亡非显著降低相关(sHR 0.749,95%CI 0.462-1.215,p=0.241),心衰事件无差异(sHR 0.986,95%CI 0.629-1.546,p=0.952),复合终点非显著获益趋势(HR 0.806,p=0.217)。NSTE-ACS亚组中心脏死亡显著降低,支持开展随机试验。

要点

  • 826例AMI-CS存活出院患者中23.8%出院时接受SGLT2抑制剂,用药者糖尿病更多、LVEF更低、SCAI休克分期更晚。
  • IPTW校正后,SGLT2抑制剂与1年心脏死亡非显著降低相关(sHR 0.749,95%CI 0.462-1.215,p=0.241)。
  • 心衰事件无差异(sHR 0.986,95%CI 0.629-1.546,p=0.952),复合终点非显著获益趋势(HR 0.806,p=0.217)。
  • NSTE-ACS亚组中SGLT2抑制剂与显著更低的心脏死亡相关。
  • 结论认为出院时使用SGLT2抑制剂可能安全且数值趋势有利,需随机试验验证。

适用人群与场景

  • 急性心肌梗死合并心源性休克(AMI-CS)后存活至出院的患者,共826例,来自多中心回顾性队列。
  • 用药组197例(23.8%)出院时处方SGLT2抑制剂,其糖尿病患病率更高、左室射血分数更低、SCAI休克分期更晚。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或目标值。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 回顾性、多中心队列研究,纳入826例AMI-CS存活出院患者,197例(23.8%)出院时接受SGLT2抑制剂,以出院为零点避免 immortal time bias,采用IPTW校正34项基线协变量。
  • 主要终点1年心脏死亡:sHR 0.749(95%CI 0.462-1.215,p=0.241),非显著降低。
  • 主要终点心衰事件:sHR 0.986(95%CI 0.629-1.546,p=0.952),无差异。
  • 复合终点:HR 0.806(p=0.217),非显著获益趋势。
  • 亚组分析:NSTE-ACS患者中SGLT2抑制剂与显著更低的心脏死亡相关。

证据类型、等级与局限

  • 证据类型:回顾性、多中心队列研究。
  • 局限:观察性设计、样本量826例、非随机、可能存在残余混杂,原文未给出证据等级或推荐强度。

对床旁实践的改变

  • 对于AMI-CS存活出院患者,出院时处方SGLT2抑制剂可能安全,但现有证据不足以将其作为常规推荐;NSTE-ACS亚组可能获益,需随机试验验证。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure and after myocardial infarction (MI), but patients with cardiogenic shock (CS) have been excluded from major trials. We therefore evaluated the association between discharge SGLT2 inhibitor prescription and 1-year outcomes in survivors of acute myocardial infarction (AMI) complicated by CS.

METHODS: This retrospective, multicenter cohort study included 826 patients who survived to hospital discharge after AMI-CS. The primary exposure was SGLT2 inhibitor prescription at discharge versus standard therapy. Time zero was defined at discharge to avoid immortal time bias. Inverse probability of treatment weighting (IPTW) using 34 baseline covariates was applied. Primary outcomes were 1-year cardiac death and heart failure (HF) events, analyzed using Fine-Gray competing risk models.

RESULTS: Of 826 patients, 197 (23.8%) received SGLT2 inhibitors. These patients had higher diabetes prevalence, lower left ventricular ejection fraction, and more advanced SCAI shock stages. After IPTW, SGLT2 inhibitor use was associated with a non-significant reduction in 1-year cardiac death (sHR 0.749, 95% CI 0.462-1.215, p=0.241) and no difference in HF events (sHR 0.986, 95% CI 0.629-1.546, p=0.952). The composite endpoint showed a non-significant trend toward benefit (HR 0.806, p=0.217). In subgroup analysis, SGLT2 inhibitor use was associated with significantly lower cardiac mortality in NSTE-ACS patients.

CONCLUSIONS: In AMI-CS survivors, SGLT2 inhibitor use at discharge could be safe and associated with favorable numerical trends, supporting the need for randomized trials.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Daoulah A, Jamjoom A, Arafat AA, et al. Sodium-Glucose Cotransporter 2 Inhibitors as Discharge Medications in Survivors of Acute Myocardial Infarction Complicated by Cardiogenic Shock. Shock. 2026. PMID: 42380740. doi:10.1097/SHK.0000000000002904

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。